Immunogenicity and Reactogenicity of a Booster Dose of a Typhoid Conjugate Vaccine (TCV) in Malawian Pre-school Children

Overview

Journal EClinicalMedicine

Specialty General Medicine

Date 2025 Mar 4

PMID 40034570

Authors

Nginache Nampota-Nkomba

Osward M Nyirenda

Shrimati Datta

Victoria Mapemba

Priyanka D Patel

Theresa Misiri

Felistas Mwakiseghile

John M Ndaferankhande

Bright Lipenga

Jennifer Oshinsky

Marcela F Pasetti

Leslie P Jamka

Melita A Gordon

Matthew B Laurens

Kathleen M Neuzil

Affiliations

Soon will be listed here.

Abstract

Background: We assessed persistence of typhoid immunity conferred by Vi polysaccharide-tetanus toxoid (Vi-TT) conjugate vaccine (TCV) four years post-vaccination and immunogenicity of a booster dose of Vi-TT given at age five.

Methods: In 2018, a phase 3 trial of Vi-TT in Malawi randomised children 1:1 to receive Vi-TT or meningococcal capsular group A conjugate vaccine (control). Subsequently, TCV was licensed and recommended in the region. In 2023, children vaccinated at 9-11 months in the original trial received a second (Booster- TCV) or first (1st-TCV) Vi-TT dose, at age five. Serum collected at days 0, 28, and 160-180 days after vaccination was tested for anti-Vi immunoglobulin (Ig)G and IgA, reported as enzyme-linked immunosorbent assay units (EU)/mL. Seroconversion was ≥4-fold rise in antibody titers from day 0 to day 28 post-vaccination. Safety outcomes included adverse events during follow-up.

Findings: We enrolled 136 children: 72 Booster-TCV and 64 1st-TCV. At baseline, anti-Vi IgG geometric mean titers (GMT) were higher in Booster-TCV (18.8 EU/mL, 95% CI 15.2-23.2) than 1st-TCV (5.7 EU/mL, 4.6-7.2) arms. GMT increased significantly between days 0 and 28 in both arms, with higher levels in Booster-TCV (6867.9 EU/mL, 5794.1-8140.6) than 1st-TCV (2912.0 EU/mL, 2429.2-3490.7) arms, representing a 375.7 and 492.6 geometric mean fold rise, respectively. On day 28, all Booster-TCV children, and all but one 1st-TCV child, seroconverted. Similar trends were seen for IgA. Vi-TT reactogenicity was similar between vaccine arms.

Interpretation: This study demonstrates sustained Vi-TT immunogenicity four years post-vaccination at 9-11 months old, and robust immune response following a booster dose at five years of age, informing policy decisions on TCV use in children.

Funding: Bill & Melinda Gates Foundation (INV-030857).

References

Qadri F, Khanam F, Liu X, Theiss-Nyland K, Biswas P, Bhuiyan A . Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet. 2021; 398(10301):675-684. PMC: 8387974. DOI: 10.1016/S0140-6736(21)01124-7. View

Yousafzai M, Karim S, Qureshi S, Kazi M, Memon H, Junejo A . Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study. Lancet Glob Health. 2021; 9(8):e1154-e1162. PMC: 8315145. DOI: 10.1016/S2214-109X(21)00255-2. View

Hoffman S, LeBoa C, Date K, Haldar P, Harvey P, Shimpi R . Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India. Clin Infect Dis. 2023; 77(1):138-144. PMC: 10320126. DOI: 10.1093/cid/ciad132. View

Nampota-Nkomba N, Carey M, Jamka L, Fecteau N, Neuzil K . Using Typhoid Conjugate Vaccines to Prevent Disease, Promote Health Equity, and Counter Drug-Resistant Typhoid Fever. Open Forum Infect Dis. 2023; 10(Suppl 1):S6-S12. PMC: 10236511. DOI: 10.1093/ofid/ofad022. View

Burrows H, Antillon M, Gauld J, Kim J, Mogasale V, Ryckman T . Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness. Vaccine. 2022; 41(4):965-975. PMC: 9880559. DOI: 10.1016/j.vaccine.2022.12.032. View

Qadri F, Khanam F, Zhang Y, Biswas P, Voysey M, Mujadidi Y . 5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial. Lancet. 2024; 404(10461):1419-1429. DOI: 10.1016/S0140-6736(24)01494-6. View

Lightowler M, Manangazira P, Nackers F, Van Herp M, Phiri I, Kuwenyi K . Effectiveness of typhoid conjugate vaccine in Zimbabwe used in response to an outbreak among children and young adults: A matched case control study. Vaccine. 2022; 40(31):4199-4210. DOI: 10.1016/j.vaccine.2022.04.093. View

Wang H, Zhang P, Zhao Q, Ma W . Global burden, trends and inequalities for typhoid and paratyphoid fever among children younger than 15 years over the past 30 years. J Travel Med. 2024; 31(8). DOI: 10.1093/jtm/taae140. View

Mohan V, Varanasi V, Singh A, Pasetti M, Levine M, Venkatesan R . Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015; 61(3):393-402. DOI: 10.1093/cid/civ295. View

10.

Meiring J, Shakya M, Khanam F, Voysey M, Phillips M, Tonks S . Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. Lancet Glob Health. 2021; 9(12):e1688-e1696. PMC: 8609278. DOI: 10.1016/S2214-109X(21)00370-3. View

11.

Ouedraogo A, Diarra A, Nebie I, Barry N, Kabore J, Tiono A . Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso. J Pediatric Infect Dis Soc. 2023; 12(9):513-518. PMC: 10533206. DOI: 10.1093/jpids/piad058. View

12.

Nampota-Nkomba N, Nyirenda O, Khonde L, Mapemba V, Mbewe M, Ndaferankhande J . Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial. Lancet Glob Health. 2022; 10(9):e1326-e1335. PMC: 9380257. DOI: 10.1016/S2214-109X(22)00275-3. View

13.

. Tetanus vaccines: WHO position paper, February 2017 - Recommendations. Vaccine. 2017; 36(25):3573-3575. DOI: 10.1016/j.vaccine.2017.02.034. View

14.

Sirima S, Ouedraogo A, Barry N, Siribie M, Tiono A, Nebie I . Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso. Int J Infect Dis. 2020; 102:517-523. PMC: 7762715. DOI: 10.1016/j.ijid.2020.10.103. View

15.

Nampota-Nkomba N, Nyirenda O, Mapemba V, Masonga R, Patel P, Misiri T . Single and two-dose typhoid conjugate vaccine safety and immunogenicity in HIV-exposed uninfected and HIV-unexposed uninfected Malawian children. Hum Vaccin Immunother. 2024; 20(1):2384760. PMC: 11404620. DOI: 10.1080/21645515.2024.2384760. View

16.

Medise B, Soedjatmiko S, Rengganis I, Gunardi H, Sekartini R, Koesno S . Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine. PLoS One. 2019; 14(2):e0211784. PMC: 6373931. DOI: 10.1371/journal.pone.0211784. View

17.

Kulkarni P, Potey A, Bharati S, Kunhihitlu A, Narasimha B, Yallapa S . The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial. Lancet. 2024; 403(10436):1554-1562. DOI: 10.1016/S0140-6736(24)00249-6. View

18.

Khanam F, Babu G, Rahman N, Liu X, Rajib N, Ahmed S . Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh. Vaccine. 2023; 41(19):3137-3140. DOI: 10.1016/j.vaccine.2023.04.014. View

19.

Tapia M, Pasetti M, Cuberos L, Sow S, Doumbia M, Bagayogo M . Measurement of tetanus antitoxin in oral fluid: a tool to conduct serosurveys. Pediatr Infect Dis J. 2006; 25(9):819-25. DOI: 10.1097/01.inf.0000232629.72160.bb. View

20.

Batool R, Yousafzai M, Qureshi S, Ali M, Sadaf T, Mehmood J . Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study. Vaccine. 2021; 39(40):5858-5865. DOI: 10.1016/j.vaccine.2021.08.051. View